Download PDF
Thorac Cardiovasc Surg 2002; 50(6): 380-383
DOI: 10.1055/s-2002-35739
Special Report
© Georg Thieme Verlag Stuttgart · New York

Jehovah's Witnesses - How to Encounter the Transfusion Issue

C.  Schmid1 , S.  Krempel2 , H.  H.  Scheld1
  • 1Department of Thoracic and Cardiovascular Surgery, Westfalische Wilhelms-Universität, Münster, Germany
  • 2Lawyer, Saarbrücken
Further Information

Publication History

Received August 18, 2002

Publication Date:
28 November 2002 (online)

    Permissions and Reprints All articles of this category

Abstract

Surgical management is different for Jehovah's Witnesses than in customary operations. Preoperative measures primarily aim at an optimal hematological condition, whereas intraoperative activities are directed towards minimizing blood loss. However, physicians taking care of Jehovah's Witnesses are not only faced with the difficulties of adequate treatment, but also by psychological and legal issues. Since the German legal system does not offer clear-cut legislation with regard to the Jehovah's Witnesses transfusion issue, guidelines have been offered on how to encounter his issue.

Key words

Open heart surgery - Jehovah's Witness - blood transfusion - legislation

References

  • 1 Lewis T P, Murphy M C, Cooley D A. Risk factors for cardiac operations in adult Jehovah's Witnesses.  Ann Thorac Surg. 1991;  51 448-450
    PubMedGoogle Scholar
  • 2 Carmichael M J, Cooley D A, Kuykendall R C, Walker W E. Cardiac surgery in children of Jehovah's Witnesses.  Tex Heart Inst J. 1985;  12 57-63
    PubMedGoogle Scholar
  • 3 McMullan D M, Beyer E AK, Gregoric I, Radovancevic B, Frazier O H. Left ventricular reduction in a Jehovah's Witness.  Ann Thorac Surg. 2000;  70 958-961
    CrossrefPubMedGoogle Scholar
  • 4 Spence R K, Alexander J B, Del Rossi A J. et al . Transfusion guidelines for cardiovascular surgery: lessons learned from operations in Jehovahs's Witnesses.  J Vasc Surg. 1992;  16 825-831
    PubMedGoogle Scholar
  • 5 Levine E, Gould A, Rosen A. et al . Perioperative recombinant human erythropoietin.  Surgery. 1989;  106 432-437
    PubMedGoogle Scholar
  • 6 Rohling R G, Zimmermann A P, Breymann C. Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin.  J Hematother Stem Cell Res. 2000;  9 497-500
    CrossrefPubMedGoogle Scholar
  • 7 Harker L A. Therapeutic cytokine stimulation of thrombocytopoiesis.  Transfus Sci. 1998;  19 149-162
    CrossrefPubMedGoogle Scholar
  • 8 Serke S. Hematopoietic growth factors as an adjunct for neutropenic patients in the ICU: still a controversial issue.  Intensive Care Med. 1999;  25 901-902
    CrossrefPubMedGoogle Scholar
  • 9 Rousou J, Levitsky S, Gonzalez-Lavin L. et al . Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study.  J Thorac Cardiovasc Surg. 1989;  97 194-203
    PubMedGoogle Scholar
  • 10 Rosolski T, Matthey T, Frick U, Hachenberg T. Blood separation with two different autotransfusion devices: effects on blood cell quality and coagulation variables.  Int J Artif Organs. 1998;  21 820-824
    PubMedGoogle Scholar
  • 11 Royston D. High-dose aprotinin therapy: a review of the first five years' experience.  J Cardiothorac Vase Anesth. 1992;  6 76-100
    PubMedGoogle Scholar
  • 12 Cosgrove D M, Heric B, Lytle B W. et al . Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.  Ann Thorac Surg. 1992;  54 1031-1038
    CrossrefPubMedGoogle Scholar
  • 13 Lemmer J H, Stanford W, Bonney S L. et al . Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency - a multicenter, randomized, double-blind, placebo-controlled study.  J Thorac Cardiovasc Surg. 1994;  107 543-553
    CrossrefPubMedGoogle Scholar
  • 14 Rosengart T K, Helm R E, Klemperer J, Krieger K H, Isom O W. Combined aprotinin and erythropoietin use for blood conservation: results in Jehovah's Witnesses.  Ann Thorac Surg. 1994;  58 1397-1403
    PubMedGoogle Scholar
  • 15 Vander Salm T J, Ansell J E, Okike O N. et al . The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study.  J Thorac Cardiovasc Surg. 1998;  95 538-540
    PubMedGoogle Scholar
  • 16 Horrow J C, Hlavacek J, Strong M D. et al . Prophylactic transexamic acid decreases bleeding after cardiac operations.  J Thorac Cardiovasc Surg. 1990;  99 70-74
    PubMedGoogle Scholar
  • 17 Casati V, Guzzon D, Oppizzi M. et al . Hemostatic effects of aprotinin, tranexamic acid and e-aminocaproic acid in primary cardiac surgery.  Ann Thorac Surg. 1999;  68 2252-2257
    CrossrefPubMedGoogle Scholar
  • 18 Mannucci P M. Desmopressin (DDAVP).  Haemophlia. 2000;  6 (Suppl 1) 60-67
    PubMedGoogle Scholar
  • 19 Levi M, Cromheecke M E, de Jonge E. et al . Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.  Lancet. 1999;  354 1940-1947
    CrossrefPubMedGoogle Scholar
  • 20 Röttgers H R, Nedjat S. Kritik am Transfusionsverbot nimmt zu.  Dtsch Ärtzebl. 2002;  99 A 102-105
    PubMedGoogle Scholar

Prof. Dr. med. Christof Schmid

Dept. of Thoracic and Cardiovascular Surgery, University Hospital

Albert-Schweitzer-Straße 33

48149 Münster

Germany

Phone: + 49-251-8357412

Fax: + 49-251-8348316

Email: schmid@uni-muenster.de

      >